Contact this trialFirst, we need to learn more about you.
Radiation
Niraparib + Dostarlimab + Radiation for Rectal Cancer
Recruiting1 awardPhase 1 & 2
Iowa City, Iowa
This trial is designed to find the best dose of niraparib to combine with dostarlimab and hypofractionated radiation for locally advanced rectal cancer, and to see what effect this has on the tumor and patient reported outcome measures.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service